<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Velasquez Garcia HA</submitter><funding>CIHR</funding><pagination>351</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10975436</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(3)</volume><pubmed_abstract>We assessed the association between cirrhosis and severe COVID-19-related outcomes among people with laboratory-diagnosed COVID-19 infection in British Columbia, Canada. We used data from the British Columbia (BC) COVID-19 Cohort, a population-based cohort that integrates data on all individuals tested for COVID-19, with data on hospitalizations, medical visits, emergency room visits, prescription drugs, chronic conditions, and deaths in the Canadian province of BC. We included all individuals aged ≥18 who tested positive for SARS-CoV-2 by real-time reverse transcription-polymerase chain reaction from 1 January 2021 to 31 December 2021. Multivariable logistic regression models were used to assess the associations of cirrhosis status with COVID-19-related hospitalization and with ICU admission. Of the 162,509 individuals who tested positive for SARS-CoV-2 and were included in the analysis, 768 (0.5%) had cirrhosis. In the multivariable models, cirrhosis was associated with increased odds of hospitalization (aOR = 1.97, 95% CI: 1.58-2.47) and ICU admission (aOR = 3.33, 95% CI: 2.56-4.35). In the analyses stratified by age, we found that the increased odds of ICU admission among people with cirrhosis were present in all the assessed age-groups. Cirrhosis is associated with increased odds of hospitalization and ICU admission among COVID-19 patients.</pubmed_abstract><journal>Viruses</journal><pubmed_title>Risk of Severe COVID-19-Related Outcomes among Patients with Cirrhosis: A Population-Based Cohort Study in Canada.</pubmed_title><pmcid>PMC10975436</pmcid><funding_grant_id>OV4-170361</funding_grant_id><pubmed_authors>Cua G</pubmed_authors><pubmed_authors>Binka M</pubmed_authors><pubmed_authors>Velasquez Garcia HA</pubmed_authors><pubmed_authors>Okonkwo-Dappa A</pubmed_authors><pubmed_authors>Wilton J</pubmed_authors><pubmed_authors>Makuza JD</pubmed_authors><pubmed_authors>Sbihi H</pubmed_authors><pubmed_authors>Janjua NZ</pubmed_authors><pubmed_authors>Adu PA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Risk of Severe COVID-19-Related Outcomes among Patients with Cirrhosis: A Population-Based Cohort Study in Canada.</name><description>We assessed the association between cirrhosis and severe COVID-19-related outcomes among people with laboratory-diagnosed COVID-19 infection in British Columbia, Canada. We used data from the British Columbia (BC) COVID-19 Cohort, a population-based cohort that integrates data on all individuals tested for COVID-19, with data on hospitalizations, medical visits, emergency room visits, prescription drugs, chronic conditions, and deaths in the Canadian province of BC. We included all individuals aged ≥18 who tested positive for SARS-CoV-2 by real-time reverse transcription-polymerase chain reaction from 1 January 2021 to 31 December 2021. Multivariable logistic regression models were used to assess the associations of cirrhosis status with COVID-19-related hospitalization and with ICU admission. Of the 162,509 individuals who tested positive for SARS-CoV-2 and were included in the analysis, 768 (0.5%) had cirrhosis. In the multivariable models, cirrhosis was associated with increased odds of hospitalization (aOR = 1.97, 95% CI: 1.58-2.47) and ICU admission (aOR = 3.33, 95% CI: 2.56-4.35). In the analyses stratified by age, we found that the increased odds of ICU admission among people with cirrhosis were present in all the assessed age-groups. Cirrhosis is associated with increased odds of hospitalization and ICU admission among COVID-19 patients.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2025-04-26T11:25:41.288Z</modification><creation>2025-04-06T13:40:11.223Z</creation></dates><accession>S-EPMC10975436</accession><cross_references><pubmed>38543717</pubmed><doi>10.3390/v16030351</doi></cross_references></HashMap>